← All trials
NCT05220397
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 11, 2022
- Primary completion
- Mar 31, 2025
- Completion date
- Mar 31, 2025
- First posted
- Feb 2, 2022
- Last posted
- Jul 15, 2022
- Enrollment
- 1200
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mayo ClinicLead sponsor
- Mayo ClinicOverall official - principal investigator
- Mayo ClinicSponsor investigator
- Janssen Pharmaceutica NVCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.